AMRS - Amyris, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.9700
-0.1200 (-3.88%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close3.0900
Open3.1300
Bid2.9500 x 4000
Ask3.0100 x 3000
Day's Range2.9100 - 3.1300
52 Week Range1.8700 - 6.0600
Volume2,523,877
Avg. Volume1,144,855
Market Cap313.344M
Beta (5Y Monthly)0.91
PE Ratio (TTM)N/A
EPS (TTM)-2.7560
Earnings DateMar 15, 2020 - Mar 19, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.50
  • How Does Amyris, Inc. (NASDAQ:AMRS) Affect Your Portfolio Volatility?
    Simply Wall St.

    How Does Amyris, Inc. (NASDAQ:AMRS) Affect Your Portfolio Volatility?

    If you own shares in Amyris, Inc. (NASDAQ:AMRS) then it's worth thinking about how it contributes to the volatility of...

  • Options Traders Expect Huge Moves in Amyris (AMRS) Stock
    Zacks

    Options Traders Expect Huge Moves in Amyris (AMRS) Stock

    Investors need to pay close attention to Amyris (AMRS) stock based on the movements in the options market lately.

  • PR Newswire

    Amyris Provides Update - Achieves Record Fourth-Quarter 2019 Product Shipments; Clean Beauty Produces Breakout Performance

    Amyris, Inc. (Nasdaq: AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today reported record production for the fourth quarter of 2019. In addition, the company's Clean Beauty business continued its breakout performance.

  • Top Marijuana Stocks for January 2020
    Investopedia

    Top Marijuana Stocks for January 2020

    The marijuana industry is made up of companies that either support or are engaged in the research, development, distribution, and sale of medical and recreational marijuana. The biggest companies include Canopy Growth Corp. (CGC), Cronos Group Inc. (CRON), and Aphria Inc. (APHA). Over the past 12 months, the marijuana industry, as measured by the ETFMG Alternative Harvest ETF (MJ) has substantially underperformed the broader market, plummeting 41.0% compared to the S&P 500's 26.4% gain. All figures in this story are as of January 8, 2020.

  • PR Newswire

    Amyris Announces Successful Shipment of First Fermentation Derived Cannabinoid to LAVVAN and Provides Business Updates

    Amyris, Inc. (Nasdaq: AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today reported that it has successfully shipped the first cannabinoid to its partner, LAVVAN. Amyris is also well on its way to the shipment of a second cannabinoid in the first half of 2020.

  • Were Hedge Funds Right Dumping Amyris Inc (AMRS)?
    Insider Monkey

    Were Hedge Funds Right Dumping Amyris Inc (AMRS)?

    Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]

  • PR Newswire

    WWD Beauty Inc Names Biossance Brand Digital Innovator Of The Year

    Biossance, a leading clean skincare brand from Amyris, Inc. (Nasdaq: AMRS), was recognized as Digital Innovator of the Year at the WWD Beauty Inc Awards for the launch of The Clean Academy, the brand's comprehensive, clean beauty education platform. Biossance President Catherine Gore accepted the award on behalf of the brand at a breakfast celebrating the winners on December 11 in New York.

  • PR Newswire

    SHAREHOLDER NOTICE: Scott+Scott Attorneys at Law LLP Continues Investigating Amyris, Inc.'s Directors and Officers for Breach of Fiduciary Duty - AMRS

    Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national securities and consumer rights litigation firm, continues investigating whether certain directors and officers of Amyris, Inc. ("Amyris" or the "Company") (NASDAQ: AMRS) breached their fiduciary duties to the Company and its shareholders. If you are an Amyris shareholder, you are encouraged to contact attorney Joe Pettigrew toll-free at (844) 818-6982 or at jpettigrew@scott-scott.com.

  • How Many Amyris, Inc. (NASDAQ:AMRS) Shares Did Insiders Buy, In The Last Year?
    Simply Wall St.

    How Many Amyris, Inc. (NASDAQ:AMRS) Shares Did Insiders Buy, In The Last Year?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...

  • PR Newswire

    Biossance Leading the Clean Beauty Revolution with Biossance.com Cyber Monday Sales up over 3X from Last Year, Marking Highest One-Day Sales in Brand History

    Biossance, a pioneering clean skincare brand from Amyris, Inc. (Nasdaq:AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced that its sales on Biossance.com for Cyber Monday, on December 2, were up over 3X from last year and resulted in the highest one-day sales in the brand's history. Product sales through Biossance.com have been comprising a greater portion of sales channel mix and these sales deliver much higher margins.

  • PR Newswire

    Amyris Engages 30-Year Wall Street Veteran to Support Capital Markets Activities & Further Balance Sheet Transformation

    Amyris, Inc. (Nasdaq:AMRS) is pleased to announce that it has entered into a consulting agreement with John Ziegelman, formerly a senior portfolio manager at Wolverine Asset Management, one of the company's top 15 shareholders. Ziegelman has over 30 years' experience investing in and advising small-cap public companies. In addition to his time with Wolverine, Ziegelman has held senior positions at Shearson-Lehman Brothers, Kidder Peabody, Citadel, and Carpe Diem Capital. Ziegelman holds an MBA from the University of Chicago and a BA from the University of Michigan. The scope of the two-year consultancy, which began on November 20, focuses on advising Amyris on supporting its capital markets activities, further simplifying the balance sheet and helping the company further diversify and increase its institutional shareholder base.

  • Thomson Reuters StreetEvents

    Edited Transcript of AMRS earnings conference call or presentation 7-Nov-19 9:30pm GMT

    Q3 2019 Amyris Inc Earnings Call

  • PR Newswire

    American Diabetes Association Announces Amyris CEO John Melo as Executive Committee Chair of 2020 Wine Country Tour de Cure

    EMERYVILLE, Calif., Nov. 19, 2019 /PRNewswire/ -- Today, the American Diabetes Association has announced that John Melo, President and CEO of Amyris, Inc. (AMRS) a science and technology company focused on Health & Clean Beauty, will chair the Executive Committee of the 2020 Wine Country Tour de Cure to be held on Sunday, May 3, 2020. Since its start in 1991, the Wine Country Tour de Cure has become a destination, marquis event for the Association annually raising millions of dollars for diabetes research, education and advocacy initiatives, including its #CountMeIn campaign.

  • PR Newswire

    Amyris Advances to Regulatory Stage with Another Significant Health & Nutrition Molecule

    EMERYVILLE, Calif., Nov. 18, 2019 /PRNewswire/ -- Amyris, Inc. (AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced that it is moving into the regulatory stage with a new, undisclosed health and nutrition molecule. Amyris has proven its capability to produce health and nutrition molecules at commercial scale with three others; artemisinin, vitamin E and, most recently, Reb M. Amyris developed a process for this ingredient that enables the highest purity at the lowest cost and has now successfully manufactured material via large scale fermentation. The company plans to submit formal regulatory filings for this ingredient (currently not being named due to partner's requirements) where required for rapid approval and market entry during the first half of 2020.

  • PR Newswire

    Amyris Closes on Exchange to Resolve CVI Heights Debt

    EMERYVILLE, Calif., Nov. 15, 2019 /PRNewswire/ -- Amyris, Inc. (AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced that it has closed on its previously announced contemplated transactions providing for the purchase of its existing CVI Heights convertible note by two "accredited investors" (as defined in Rule 501 of Regulation D promulgated under the Securities Act of 1933) and subsequent exchange of such note for new unsecured convertible senior notes (the "Notes") in the amount of $66 million in a private exchange. The CVI Heights debt has been retired, thus curing the prior default of this debt. "We are pleased to have closed on these transactions and to have financed the resolution of our CVI Heights debt at a low coupon rate of 5%," said John Melo, Amyris President and CEO.

  • PR Newswire

    Amyris Executes Agreements to Resolve CVI Heights Debt

    EMERYVILLE, Calif., Nov. 11, 2019 /PRNewswire/ -- Amyris, Inc. (AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced that definitive agreements have been entered into providing for the purchase of its existing CVI Heights convertible note by two "accredited investors" (as defined in Rule 501 of Regulation D promulgated under the Securities Act of 1933) and subsequent exchange of such note for new unsecured convertible senior notes (the "Notes") in the amount of $66 million in a private exchange. As a result, the CVI Heights debt will be retired, thus curing the prior default of this debt, and Amyris will incur the new Notes as debt. The company can redeem the Notes at any time at a 15% premium to the greater of the principal amount or conversion value.

  • PR Newswire

    Amyris Continues to Deliver Strong Revenue Growth

    - Q3 2019 GAAP revenue of $35.0 million , up 144% over GAAP revenue of $14.3 million for Q3 2018 - Year to date GAAP revenue of $112.0 million , up 137% over $47.2 million for the prior year period - Product ...

  • Business Wire

    Haeggquist & Eck, LLP Investigates Amyris Officers and Directors Regarding Restatement of Financial Results

    Haeggquist & Eck, LLP, a leading shareholder rights litigation firm, is investigating whether certain directors and officers of Amyris, Inc. (“Amyris” or the “Company”) (AMRS) breached their fiduciary duties to the Company and its shareholders. If you are an Amyris shareholder, you are encouraged to contact Amber Eck at Haeggquist & Eck for additional information. Amyris is an industrial biotech company that develops and produces chemical ingredients, including flavors and fragrance, cosmetics ingredients, pharmaceuticals, and nutraceuticals.

  • PR Newswire

    Amyris to Announce Third Quarter Financial Results on Thursday, November 7, 2019

    EMERYVILLE, Calif. , Oct. 23, 2019 /PRNewswire/ -- Amyris, Inc. (Nasdaq:AMRS) will report financial results for the third quarter ended September 30, 2019 after market close on Thursday, November 7, 2019 ...

  • WeissLaw LLP: Amyris, Inc. is the Subject of a Legal Investigation
    PR Newswire

    WeissLaw LLP: Amyris, Inc. is the Subject of a Legal Investigation

    NEW YORK, Oct. 18, 2019 /PRNewswire/ -- WeissLaw LLP, a national class action and shareholders' rights law firm with offices in New York, Los Angeles and Atlanta, announces the investigation of Amyris, Inc. (AMRS) ("AMRS," or the "Company"), its Board of Directors, and certain Company officers for, among other things, possible breaches of fiduciary duty and violations of federal securities laws.

  • PR Newswire

    Amyris Pipette Brand Successfully Launches on Amazon.com

    EMERYVILLE, Calif., Oct. 10, 2019 /PRNewswire/ -- Amyris, Inc. (AMRS), a leader in the development and production of sustainable products for Health and Clean Beauty, today announced the successful launch of its Pipette brand on Amazon.com. As of October 3, Pipette was available at Pipettebaby.com, buybuyBABY.com, Amazon.com, and Dermstore.com with very strong early results and significant positive feedback from consumers. Pipette is expected to drive strong top-line sales performance for Amyris in the fourth quarter and beyond.

  • PR Newswire

    Amyris Files Form 10-Qs to Achieve Compliance - Notes Receipt of Nasdaq Deficiency Notification

    EMERYVILLE, Calif., Oct. 7, 2019 /PRNewswire/ -- Amyris, Inc. (AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today reported that it has filed its required Forms 10-Q for the first quarter ended March 31, 2019 and the second quarter ended June 30, 2019. The company also noted that it has received a standard notice from Nasdaq stating that, as a result of not having timely filed these quarterly reports on Form 10-Q in accordance with the required September 30 deadline, it was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires timely filing of periodic financial reports with the Securities and Exchange Commission. Upon the filing of the company's quarterly reports for the first and second quarters of 2019 on October 7, the company received a second notice from Nasdaq confirming that the company was again in compliance with the Rule and that, as a result, the company was no longer subject to Nasdaq's suspension and delisting procedures.

  • Thomson Reuters StreetEvents

    Edited Transcript of AMRS earnings conference call or presentation 2-Oct-19 8:30pm GMT

    Q2 2019 Amyris Inc Earnings Call